Filing Analysis
AEON Biopharma, Inc. has filed an 8-K to announce its financial results for the second quarter ended June 30, 2026, and provided a corporate presentation via Regulation FD disclosure.
📋 Key Facts
- Reported financial results for Q2 ended June 30, 2026 (Item 2.02).
- Released a Corporate Presentation to the investor relations section of its website (Item 7.01).
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
AEON Biopharma has regained compliance with NYSE American continued listing standards, resolving previous deficiencies under Sections 1003(a)(i) and (ii). The company expects the '.BC' indicator to be removed from its trading symbol.
🚩 Red Flags
- Previous delisting risk/non-compliance status indicated by the '.BC' trading symbol indicator.
- Risk of future non-compliance remains as the company must continue to meet all listing standards.
📋 Key Facts
- Company received a letter from NYSE Regulation confirming compliance with all NYSE American continued listing standards.
- Resolved deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide.
- The '.BC' (below compliance) indicator is expected to be removed from the ticker 'AEON'.
- Company will no longer appear on the list of noncompliant issuers on the NYSE American website.
AEON Biopharma completed the sale of 4,696,102 shares of Class A common stock following the partial exercise of an over-allotment option by underwriters. This transaction generated approximately $1.5 million in gross proceeds.
🚩 Red Flags
- Dilution: The issuance of over 4.6 million new shares increases the total share count, diluting existing shareholders.
- Capital Intensity: Small net proceeds ($1.4M) relative to the scale of equity issuances suggest a high burn rate or continuous need for external financing.
📋 Key Facts
- Underwriters exercised a partial over-allotment option on July 23, 2026.
- 4,696,102 shares of Class A common stock were issued and sold.
- Gross proceeds from this specific tranche: approximately $1.5 million.
- Net proceeds after commissions/discounts: approximately $1.4 million.
- Previous milestone warrants (two-year and five-year) had already been exercised for 6,403,290 shares or pre-funded warrants.
AEON Biopharma completed a significant public offering of common stock and pre-funded warrants on July 15, 2026, raising approximately $12.2 million in net proceeds. The offering includes complex milestone warrants tied to FDA regulatory progress for their ABP-450 biosimilar program.
🚩 Red Flags
- Significant dilution: The issuance of nearly 25 million pre-funded warrants and millions of common/milestone shares will result in massive shareholder dilution.
- Complex warrant structure: Milestone warrants are tied to specific regulatory outcomes (FDA Type 2B minutes), creating potential 'death spiral' or heavy dilution triggers if clinical milestones are met.
- Variable Rate Transaction restriction: The company is prohibited from entering into variable rate transactions for up to 180 days, suggesting a need to avoid predatory financing structures.
- Low share price context: Offering prices around $0.32 suggest the company is operating in a low-stock-price environment typical of distressed micro-caps.
📋 Key Facts
- Offering closed on July 15, 2026.
- Net proceeds of approximately $12.2 million raised after expenses and commissions.
- Issued 17,851,599 shares of Class A common stock at $0.3221 per share (combined with milestone warrants).
- Issued 24,837,008 pre-funded warrants at $0.3220 per warrant.
- Includes Two-Year Milestone Warrants and Five-Year Milestone Warrants tied to FDA Type 2B meeting minutes and Phase 3 clinical trials of ABP-450.
- The Representative (Lake Street Capital Markets) exercised an over-allotment option for 6,403,290 shares/warrants on July 14, 2026.
AEON Biopharma reported the results of its Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected two Class III directors and ratified the appointment of KPMG LLP as the independent auditor for the 2026 fiscal year.
📋 Key Facts
- Marc Forth and Seongsoo Park were elected as Class III directors for three-year terms ending in 2029.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Voting for the auditor ratification was overwhelmingly positive, with 21,502,418 votes 'For' and only 18,217 'Against'.
AEON Biopharma, Inc. updated its corporate presentation on May 14, 2026, making it available on its website for use in future investor meetings. The filing serves as a standard Regulation FD disclosure to ensure public access to management's presentation materials.
📋 Key Facts
- AEON Biopharma updated its corporate presentation on May 14, 2026.
- The presentation is furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure).
- The information is intended for use in future meetings with investors and management.
- The filing is not considered "filed" for purposes of Section 18 of the Exchange Act.
AEON Biopharma, Inc. announced its financial results for the first fiscal quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- Report filed under Item 2.02 (Results of Operations and Financial Condition)
- Press release dated May 14, 2026, included as Exhibit 99.1
- Company is classified as an emerging growth company
AEON Biopharma received an additional notice of non-compliance from NYSE American on March 31, 2026, due to a stockholders' deficit of approximately $55 million. This follows a previous non-compliance notice from February 2025, with a final deadline to regain compliance by August 3, 2026.
🚩 Red Flags
- Substantial stockholders' deficit of $55 million against a $4 million requirement.
- Multiple 8-K items/notices regarding listing non-compliance (Section 1003(a)(i) and 1003(a)(ii)).
- Persistent history of net losses in three of the last four fiscal years.
- Tight deadline (August 3, 2026) to bridge a massive equity gap.
📋 Key Facts
- Received notice of non-compliance with Section 1003(a)(ii) of the NYSE American Company Guide on March 31, 2026.
- Reported a stockholders' deficit of approximately $55 million as of December 31, 2025.
- The company has reported net losses in three of its four most recent fiscal years.
- Previously received a notice for failing Section 1003(a)(i) in February 2025.
- The NYSE American has granted a compliance plan period ending August 3, 2026.
- The stock continues to trade with a '.BC' (below compliance) indicator.
AEON Biopharma, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 30, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The report was filed on March 30, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The financial information was furnished as Exhibit 99.1 and is not considered 'filed' under Section 18 of the Exchange Act.
AEON Biopharma appointed John Bencich as CFO and updated the employment agreement for CAO Jennifer Sy. The filing reveals the company is currently non-compliant with NYSE American listing standards, as a portion of the new CFO's equity compensation is tied to regaining compliance.
🚩 Red Flags
- Disclosure of NYSE American listing non-compliance (implied by PSU vesting conditions).
- Expansion of the Inducement Plan by 1,000,000 shares without shareholder approval, leading to potential dilution.
- Generous 'Change in Control' severance packages (12 months salary/bonus) for both the new CFO and CAO.
📋 Key Facts
- John Bencich appointed CFO effective March 9, 2026, and Principal Financial Officer effective April 1, 2026.
- Mr. Bencich's compensation includes a $450,000 base salary, a 40% target bonus, and 754,717 RSUs.
- The company granted 235,849 PSUs to the CFO that vest only after the company regains compliance with NYSE American continued listing standards.
- The Board added 1,000,000 shares to the 2025 Employment Inducement Incentive Award Plan without stockholder approval.
- CAO Jennifer Sy entered into a formal employment agreement with a $275,000 base salary and updated severance terms.
AEON Biopharma completed a debt-for-equity exchange with Daewoong Pharmaceutical to satisfy $15M in old notes, resulting in significant dilution. The company also received stockholder approval for an expanded equity plan and a PIPE financing second closing.
🚩 Red Flags
- Significant equity dilution: Issuance of ~11.9M shares and ~11.2M warrants to satisfy debt.
- Heavy reliance on a single major creditor (Daewoong) for debt restructuring and potential future ownership.
- Complex capital structure involving multiple layers of warrants, pre-funded warrants, and convertible notes.
📋 Key Facts
- Exchanged up to $15,000,000 of senior secured convertible notes (Old Notes) with Daewoong Pharmaceutical.
- Issued 11,918,380 new shares of Common Stock and 11,236,631 pre-funded warrants to Daewoong as part of the exchange.
- Issued a new $1,500,000 senior secured convertible note (New Note) to Daewoong.
- Warrants issued to Daewoong for up to 8,000,000 shares at an exercise price of $1.09392 per share.
- Stockholders approved the 'PIPE Financing Proposal' and a new '2023 Incentive Award Plan'.
- Post-exchange total outstanding common stock: 24,024,282 shares (as of Jan 21, 2026).
- Second closing of Private Placement expected the week of January 26, 2026.
AEON Biopharma, Inc. has released a new Corporate Presentation via its investor relations website to provide updated information regarding the company's business and operations.
📋 Key Facts
- The company made a 'Corporate Presentation' available on January 12, 2026.
- The presentation is furnished as Exhibit 99.1 and is intended for use in future management meetings.
- Information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 liability.
AEON Biopharma entered into an Exchange Agreement with Daewoong Pharmaceuticals to exchange existing senior secured convertible notes for a combination of new common stock, pre-funded warrants, and a new $1.5 million senior secured convertible note. The deal includes significant dilution via approximately 23.1 million new shares and features aggressive anti-dilution protections.
🚩 Red Flags
- Significant potential dilution: The issuance of ~23.1 million shares is substantial for a micro-cap company.
- Aggressive anti-dilution terms: Warrants include 'full ratchet' protection, which is highly dilutive to existing shareholders in the event of future down rounds.
- Debt covenants: The new note restricts the company from issuing senior or pari passu debt without Daewoong's consent.
- Security interest: Daewoong holds a first-priority security interest on substantially all assets, increasing creditor risk.
📋 Key Facts
- Exchange involves existing Convertible Notes held by Daewoong being exchanged for common stock/warrants and a new $1.5M senior secured convertible note.
- Estimated issuance of approximately 23.1 million shares of Common Stock (subject to stockholder approval).
- The New Convertible Note carries a high interest rate of 15.79% payable in cash at maturity (April 12, 2030).
- Includes warrants to purchase up to 8,000,000 shares at $1.09392 per share.
- The agreement includes a 'full ratchet' anti-dilution protection for the Common Stock Warrant.
- Daewoong receives a first-priority security interest on substantially all of AEON's assets.
AEON Biopharma, Inc. filed an 8-K to disclose a new corporate presentation made available on its website via Regulation FD disclosure.
📋 Key Facts
- The company released a 'Corporate Presentation' dated December 2025.
- The filing is intended to satisfy Regulation FD requirements by making information publicly available in the investor relations section of their website.
- The presentation contains forward-looking statements as noted in Exhibit 99.1.
AEON Biopharma, Inc. announced its financial results for the third quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025
- Announcement date: November 14, 2025
- The company is classified as an emerging growth company.
AEON Biopharma entered into a Securities Purchase Agreement for a two-stage private placement of common stock and warrants, alongside a term sheet to exchange existing debt with Daewoong Pharmaceutical for new notes, equity, and significant warrants. The transactions involve substantial potential dilution through the issuance of millions of shares and warrants.
🚩 Red Flags
- Significant potential dilution from the issuance of approximately 23.1 million exchange shares and millions of additional warrants.
- Full ratchet anti-dilution protection for certain warrants, which can heavily dilute existing shareholders during corporate actions.
- Complex multi-stage financing structure involving both new private placement investors and debt conversion by an existing creditor (Daewoong).
- Requirement for stockholder approval for the second closing and the debt exchange.
📋 Key Facts
- Private Placement: Issuance of 1,964,905 shares/pre-funded warrants at First Closing (expected week of Nov 17, 2025) at $0.9116 per share.
- Second Closing: Expected issuance of 4,616,924 shares and 6,581,829 warrants, subject to stockholder approval and a transaction with Daewoong.
- Debt Exchange: Term sheet with Daewoong Pharmaceutical to exchange existing senior secured convertible notes for a $1.5M new note, ~23.1 million 'Exchange Shares', and 8 million warrants.
- Warrant Terms: Warrants have an exercise price of $1.09392 per share; Pre-Funded Warrants/True-Up Warrants have an exercise price of $0.0001.
- Anti-dilution: Warrants include full ratchet anti-dilution protection, subject to a floor of $0.30387 per share.
AEON Biopharma, Inc. filed an 8-K to disclose a new Corporate Presentation made available on its website as part of Regulation FD disclosure.
📋 Key Facts
- The company released a 'Corporate Presentation' dated September 2025 via its investor relations website.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
- The filing includes an interactive data file (XBRL).
AEON Biopharma, Inc. announced its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The company is classified as an 'emerging growth company' under SEC rules.
AEON Biopharma, Inc. held its Annual Meeting of Stockholders on June 13, 2025, to vote on director elections and the appointment of independent auditors.
📋 Key Facts
- Annual Meeting of Stockholders held on June 13, 2025.
- Jost Fischer was elected as Class II Director for a term ending in 2028 (661,774 votes 'For').
- Eric Carter was elected as Class II Director for a term ending in 2028 (674,894 votes 'For').
- Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2025.
- The meeting results were certified by the Company’s inspector of elections.
AEON Biopharma, Inc. has filed an 8-K to furnish a corporate presentation via its website under Regulation FD disclosure. The filing does not contain material financial changes or structural updates.
📋 Key Facts
- Company released a new 'Corporate Presentation' dated May 2025.
- The information is being made available in the investor relations section of the company's website.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
AEON Biopharma, Inc. announced its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notice of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025.
- Announcement date: May 14, 2025.
- The company is classified as an 'emerging growth company'.
- Financial results were released via a press release furnished in Exhibit 99.1.
AEON Biopharma has received acceptance from the NYSE American for its compliance plan to address previous non-compliance with continued listing standards. The company has been granted a grace period until August 3, 2026, to regain full compliance.
🚩 Red Flags
- Ongoing non-compliance with NYSE American continued listing standards (Sections 1003(a)(i), (ii) and (iii)).
- Risk of delisting if progress is deemed insufficient by the exchange before August 2026.
📋 Key Facts
- NYSE American accepted the Company's compliance plan on April 22, 2025.
- The Plan Period to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide extends until August 3, 2026.
- Shares continue to trade on the NYSE American under the symbol 'AEON'.
- The company is required to make sufficient progress consistent with the Plan during the Plan Period to avoid delisting proceedings.
AEON Biopharma has appointed Robert Bancroft as President and CEO, effective April 29, 2025. The current Interim CEO, Jost Fisher, will transition to a role as Chairman of the Board and head of the audit and compensation committees.
🚩 Red Flags
- Leadership transition from an interim CEO (Jost Fisher) suggests a period of management instability or transition.
- The adoption of a new Inducement Plan without stockholder approval is common but can lead to future dilution.
📋 Key Facts
- Robert Bancroft appointed as Principal Executive Officer, President, and CEO, effective April 29, 2025.
- Bancroft's background includes leadership roles at Revance Therapeutics and Smith & Nephew.
- Base salary for the new CEO is $425,000 per year with a target annual cash bonus of 50% of base salary.
- Equity compensation includes 59,034 stock options and 177,103 Restricted Stock Units (RSUs) on a four-year vesting schedule.
- The Board adopted the '2025 Employment Inducement Incentive Award Plan' to reserve 1,000,000 shares for new hires.
AEON Biopharma has announced significant leadership changes, including the formal appointment of Board Chairman Jost Fischer as Interim CEO and President, effective April 4, 2025. Additionally, Jennifer Sy has been promoted to Chief Accounting Officer and Principal Financial Officer.
🚩 Red Flags
- Leadership instability: The use of an 'Interim' CEO suggests the company is in a transitional phase or lacks a permanent successor.
- Succession risk: Rapid changes in top-tier management (CEO and PFO) can indicate internal volatility.
📋 Key Facts
- Jost Fischer (Chairman of the Board) appointed as Interim CEO and President, effective April 4, 2025.
- Jennifer Sy promoted from VP, Corporate Controller to Chief Accounting Officer and Principal Financial Officer, effective April 4, 2025.
- Ms. Sy's base salary increased from $245,000 to $275,000 in connection with her promotion.
- The appointment of Mr. Fischer follows a previous disclosure on March 27, 2025.
AEON Biopharma announced the resignation of President and CEO Marc Forth, effective April 4, 2025. The Board has appointed Chairman Jost Fischer as Interim CEO while a permanent replacement is sought.
🚩 Red Flags
- Sudden leadership transition in the CEO role can create operational uncertainty during a search for permanent management.
📋 Key Facts
- Marc Forth to resign as President and CEO on April 4, 2025.
- Mr. Forth will remain on the Board of Directors to provide strategic guidance.
- Jost Fischer (current Chairman) appointed as Interim CEO.
- The departure is stated not to be due to any disagreement regarding Company operations, policies, or practices.
- Interim CEO Jost Fischer has extensive executive experience, including former roles at Sirona and The Hoermann Group.
AEON Biopharma, Inc. announced its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the company's annual performance via an accompanying press release.
📋 Key Facts
- Report date: March 24, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 containing the full financial results.
- Company is an emerging growth company.
AEON Biopharma, Inc. filed an 8-K to disclose a new corporate presentation made available on its website via Regulation FD disclosure.
📋 Key Facts
- The company released a 'Corporate Presentation' dated March 2025.
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- The information provided in the presentation is intended for investor relations and future management meetings.
AEON Biopharma, Inc. has announced a 1-for-72 reverse stock split following stockholder approval at a special meeting held on February 24, 2025. The split is intended to reduce the total number of outstanding shares from approximately 79.9 million to approximately 1.1 million.
🚩 Red Flags
- Reverse stock split (typically used to maintain exchange listing requirements or improve share price)
- Significant reduction in float/share count from ~79.9M to ~1.1M
- Implicit compliance action for NYSE American listing rules (referenced via Proposal 3)
📋 Key Facts
- Reverse stock split ratio: 1-for-72
- Effective Date: February 26, 2025, at 12:01 a.m. ET
- Pre-split shares outstanding: ~79.9 million
- Post-split shares outstanding: ~1.1 million
- Authorized share increase: From 500,000,000 to 1,040,000,000 shares approved
- New CUSIP number: 00791X 209
- The split will affect equity awards and warrants proportionally.
AEON Biopharma received a notice from NYSE American stating it is non-compliant with continued listing standards due to failing the minimum stockholders' equity requirement. The company reported a stockholders' deficit of $32.1 million as of September 30, 2024.
🚩 Red Flags
- Delisting notice from NYSE American
- Significant stockholders' deficit of $32.1 million
- History of net losses in two of the three most recent fiscal years
- No current eligibility for exemptions from the equity requirement
📋 Key Facts
- Received written notice of non-compliance from NYSE American on February 3, 2025.
- Non-compliance is due to failing the minimum stockholders' equity requirement (Section 1003(a)(i) of the Company Guide).
- Reported a stockholders' deficit of $32.1 million at September 30, 2024.
- The company has an 18-month compliance period to regain compliance by August 3, 2026.
- A plan to regain compliance must be submitted to the NYSE American by March 5, 2025.
AEON Biopharma, Inc. completed a significant public offering of 40 million Common Units (stock and warrants) to Aegis Capital Corp., raising approximately $18.3 million in net proceeds for working capital.
🚩 Red Flags
- Significant dilution: The issuance of 40 million units represents a massive increase in the share count relative to the post-offering float (approx. 50% increase).
- Warrant overhang: The inclusion of Series A and B warrants at $0.625 creates significant potential for future dilution.
- Use of proceeds is for 'general corporate purposes, including working capital,' which often indicates a need to extend cash runway due to high burn rates.
📋 Key Facts
- Offered 40,000,000 Common Units consisting of one share of Common Stock and two warrants (Series A and Series B).
- Warrants have an exercise price of $0.625 per share.
- Aegis Capital Corp. exercised an over-allotment option for 6,000,000 Series A and 6,000,000 Series B Warrants on January 7, 2025.
- Net proceeds from the offering totaled approximately $18.3 million.
- Post-offering common stock outstanding: 79,970,693 shares.
AEON Biopharma, Inc. issued a press release on January 6, 2025, regarding pricing for a securities offering.
🚩 Red Flags
- Potential dilution for existing shareholders due to the pricing of a securities offering.
📋 Key Facts
- The company issued a press release dated January 6, 2025, specifically regarding 'Pricing'.
- The filing is an 8-K filed under Item 7.01 (Regulation FD Disclosure).
- The registrant is classified as an emerging growth company.
AEON Biopharma, Inc. amended its bylaws to reduce the quorum requirement for shareholder meetings from a majority of outstanding shares to 33.34% of voting power.
🚩 Red Flags
- Lowering quorum requirements can sometimes be used by management to facilitate corporate actions (like mergers or acquisitions) with less shareholder participation, though it is a common governance adjustment.
📋 Key Facts
- Amendment effective date: December 18, 2024
- Old quorum requirement: Majority of outstanding shares entitled to vote
- New quorum requirement: 33.34% of the voting power of outstanding shares entitled to vote
- The change was implemented via a Certificate of Amendment to the Bylaws.
AEON Biopharma, Inc. announced its financial results for the fiscal quarter ended September 30, 2024. The filing serves as a formal notification of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Fiscal quarter ended September 30, 2024.
- Announcement date: November 13, 2024.
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
AEON Biopharma, Inc. filed an 8-K to furnish a new corporate presentation via its website under Regulation FD disclosure.
📋 Key Facts
- The company released an updated Corporate Presentation dated October 2024.
- The filing was made pursuant to Item 7.01 (Regulation FD Disclosure).
- Information in the presentation is intended for investor relations and future management meetings.
AEON Biopharma, Inc. announced its financial results for the fiscal quarter ended June 30, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Fiscal quarter ended June 30, 2024
- The company is classified as an 'emerging growth company'
- Financial results were furnished via Exhibit 99.1 (Press Release)
AEON Biopharma, Inc. has released an updated corporate presentation via its website to provide information to investors. This filing is a standard Regulation FD disclosure intended to make management's messaging publicly available.
📋 Key Facts
- The company made a new Corporate Presentation available on August 6, 2024.
- The presentation was furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
- The filing includes standard forward-looking statement disclaimers.
AEON Biopharma announced a strategic reprioritization to pursue the 351(k) biosimilar regulatory pathway for its lead candidate, ABP-450, using AbbVie's BOTOX as the reference product. The company plans to advance a single pivotal clinical study in cervical dystonia following FDA consultation.
🚩 Red Flags
- Reprioritization of clinical development strategy often indicates a need to optimize limited capital/resources.
📋 Key Facts
- Strategic shift to 351(k) biosimilar regulatory pathway for lead candidate ABP-450.
- AbbVie Inc.’s BOTOX identified as the reference product.
- Plan to advance a single pivotal clinical development study in cervical dystonia.
- A successful Phase 3 comparative study could support similarity across all eight currently approved and future therapeutic indications.
- Biosimilar Initial Advisory Meeting with the FDA is scheduled for Q3 2024.
AEON Biopharma, Inc. held its Annual Meeting of Stockholders on June 14, 2024, reporting the results of three shareholder proposals. The meeting included the election of two directors and approval for a potential significant equity issuance to Daewoong Pharmaceuticals Co. LTD.
🚩 Red Flags
- Approval of potential issuance to Daewoong Pharmaceuticals representing a 'change of control' suggests significant dilution and shift in company ownership/control structure.
📋 Key Facts
- Annual Meeting held on June 14, 2024.
- Robert Palmisano elected as Class I Director (term ending 2027) with 24,463,654 votes 'For'.
- Shelley Thunen elected as Class I Director (term ending 2027) with 24,431,564 votes 'For'.
- Stockholders approved a potential issuance to Daewoong Pharmaceuticals Co. LTD. of Class A common stock equal to 20% or more of outstanding stock.
- The Daewoong issuance was approved as a 'change of control' under NYSE American rules (Proposal 2).
- KPMG LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
AEON Biopharma has terminated its CFO, Peter Reynolds, and simultaneously discontinued its Phase 2 migraine study (ABP-450) to conserve cash. The CEO will assume the role of Principal Financial Officer while a new Principal Accounting Officer is appointed.
🚩 Red Flags
- Simultaneous departure of CFO/PFO/PAO and discontinuation of a clinical program.
- Clinical failure: ABP-450 failed primary and secondary endpoints in the chronic migraine cohort.
- Cash conservation measures indicate potential liquidity constraints or strategic pivot.
- Multiple 8-K items (Officer Departure + Other Events) increase signal complexity.
📋 Key Facts
- Termination of Peter Reynolds as CFO, PFO, and PAO effective May 17, 2024.
- CEO Marc Forth appointed as interim Principal Financial Officer (no additional compensation).
- Jennifer Sy (VP, Corporate Controller) appointed as Principal Accounting Officer.
- Discontinuation of Phase 2 double-blind study of ABP-450 for migraine treatment.
- Cessation of enrollment and dosing in the Open Label Extension (OLE) study.
- The Migraine Study failed to meet primary endpoints in both episodic and chronic cohorts.
AEON Biopharma, Inc. announced its financial results for the fiscal quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended March 31, 2024.
- Announcement date: May 14, 2024.
- The company is classified as an 'emerging growth company'.
- Financial results were furnished via press release in Exhibit 99.1.
AEON Biopharma is restating its financial statements for the periods ended September 30, 2023, and December 31, 2023, due to a significant error in accounting for acquired in-process research and development (IPR&D). The company also expects to disclose substantial doubt regarding its ability to continue as a going concern.
🚩 Red Flags
- Going concern language: Company anticipates disclosing substantial doubt about its ability to continue as a going concern for at least 12 months from the expected issuance of the next 10-Q.
- Material restatement involving a $348 million loss adjustment.
- Expected material weakness in internal controls over financial reporting.
- Potential delisting risk mentioned in forward-looking cautionary notes (implied by context of liquidity/compliance).
📋 Key Facts
- Restatement affects Form 10-Q for three/nine months ended Sept 30, 2023, and Form 10-K for year ended Dec 31, 2023.
- The error involves the improper write-off of acquired IPR&D at the close of a merger; it should have been reflected on the opening balance sheet rather than in accumulated deficit.
- Non-cash corrections will increase reported losses by $348.0 million for the periods July 22, 2023, to Sept 30, 2023, and July 22, 2023, to Dec 31, 2023.
- The error had no impact on cash balances or operating cash flows.
- Company expects to report a material weakness in internal controls related to this error.
AEON Biopharma announced preliminary top-line results from its Phase 2 interim analysis of ABP-450 for chronic migraine treatment. The study failed to meet its primary endpoint or any secondary endpoints, as the active arms did not show statistically significant differences compared to a high-performing placebo group.
🚩 Red Flags
- Failure to meet primary endpoint in Phase 2 clinical trial.
- High placebo effect (8.4 days reduction) potentially compromising the study's ability to demonstrate efficacy.
- Clinical failure of a lead asset (ABP-450) significantly impacts company valuation and pipeline prospects.
📋 Key Facts
- Phase 2 interim analysis of ABP-450 in preventative treatment of chronic migraine.
- Total patients analyzed: 325 randomized across three arms.
- Primary endpoint (mean reduction in monthly migraine days - MMD) results: 150 U arm (-8.5 days), 195 U arm (-7.7 days), Placebo arm (-8.4 days).
- Statistical significance failed for primary endpoint (p=0.9132 for 150U; p=0.3611 for 195U).
- Placebo group showed a much higher reduction in MMD than expected.
- No secondary endpoints met statistical significance.
AEON Biopharma has closed a $10.0 million tranche of a senior secured convertible note issuance to Daewoong Pharmaceutical Co., LTD. This follows a previous $5.0 million sale, bringing the total under the existing subscription agreement closer to its $15.0 million cap.
🚩 Red Flags
- High interest rate (15.79%) on secured debt indicates significant cost of capital and potential liquidity pressure.
- The use of 'senior secured' convertible notes suggests the lender has priority claim over assets in a liquidation scenario.
- Heavy reliance on a single strategic investor (Daewoong) for financing, creating concentrated dependency.
📋 Key Facts
- Issued and sold a $10.0 million senior secured convertible note to Daewoong Pharmaceutical Co., LTD on April 12, 2024.
- The note carries an annual interest rate of 15.79% and matures on April 12, 2027.
- Proceeds are earmarked for late-stage clinical development of lead candidate ABP-450 and general working capital.
- Seongsoo Park, CEO of Daewoong Pharmaceutical, was appointed to the AEON Board of Directors as a Class III director effective April 12, 2024.
AEON Biopharma has issued a supplemental notice regarding the redemption of all outstanding public warrants. The company has set a Redemption Fair Market Value of $7.6994, with a cashless exercise ratio of approximately 0.2456 shares per warrant.
🚩 Red Flags
- Forced redemption of warrants can lead to significant dilution or sudden loss of value for warrant holders if they fail to act before the deadline.
📋 Key Facts
- Redemption Date: April 29, 2024
- Redemption Fair Market Value: $7.6994 per share
- Cashless Exercise Ratio: Approximately 0.2456 shares of Common Stock per Public Warrant
- Unexercised Warrants after Redemption Date will be void and worth only $0.10 per warrant
AEON Biopharma, Inc. announced the redemption of all outstanding warrants to purchase Class A common stock that were issued during its initial public offering under a February 8, 2021 agreement.
🚩 Red Flags
- None identified in this specific filing
📋 Key Facts
- Redemption date: March 29, 2024
- Warrants being redeemed are those issued as part of the units sold in the Company's IPO
- The redemption is conducted pursuant to Section 6.2 of the Warrant Agreement dated February 8, 2021
- The warrant agent is Continental Stock Transfer & Trust Company
AEON Biopharma, Inc. announced its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's annual earnings and financial position.
📋 Key Facts
- Report date: March 29, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
AEON Biopharma has completed the initial closing of a $5.0 million senior secured convertible note issuance to Daewoong Pharmaceutical Co., LTD. The proceeds are intended for late-stage clinical development of ABP-450 and working capital.
🚩 Red Flags
- High interest rate (15.79%) indicating high perceived risk by the lender.
- Senior secured status: Lender has a first-priority security interest on substantially all assets, including potential foreclosure rights upon default.
- Restrictive covenants: The company is limited from issuing senior or pari passu debt without Daewoong's consent.
- Potential for significant dilution due to the 1.3x conversion premium and automatic conversion triggers.
📋 Key Facts
- Initial closing on March 24, 2024, for $5,000,000 in senior secured convertible notes.
- Total potential issuance under the subscription agreement is up to $15.0 million.
- The note carries a high annual interest rate of 15.79%.
- Maturity date is set for March 24, 2027.
- Conversion feature includes a 1.3x premium on the conversion price under specific conditions (Qualified Financing or positive Phase 3 clinical data).
- The note is secured by a first-priority security interest on substantially all of the company's assets.
AEON Biopharma entered into a subscription agreement with Daewoong Pharmaceutical for up to $15.0 million in senior secured convertible notes to fund clinical development of ABP-450. The deal includes significant provisions such as board representation for the lender, high interest rates (15.79%), and potential dilution through conversion features.
🚩 Red Flags
- High interest rate (15.79%) indicating high perceived risk by the lender.
- Senior secured status: Lender has first-priority claim on substantially all company assets.
- Significant dilution potential via conversion features and 'Conversion Cap' bypass requiring stockholder approval.
- Termination Purchase Right: Potential loss of core intellectual property (ABP-450 Know-How) for $1.00 if clinical/commercial milestones are missed.
- Multiple 8-K items detected (Material Agreement + Termination of previous agreements).
📋 Key Facts
- Total financing amount: Up to $15.0 million via senior secured convertible notes.
- Initial closing of $5.0 million scheduled within 10 days of March 19, 2024; subsequent $10.0 million closing subject to conditions including a license agreement amendment.
- Interest rate: 15.79% per annum with a 3-year maturity.
- Security: First-priority security interest on substantially all company and subsidiary assets.
- Daewoong gains the right to appoint one senior management member to the Board of Directors.
- Conversion features include an automatic conversion upon a $30M+ qualified financing or optional conversion upon positive Phase 3 clinical data for ABP-450.
- The deal includes a 'Termination Purchase Right' allowing Daewoong to buy all Know-How related to ABP-450 for $1.00 if certain commercialization/clinical milestones are not met.
AEON Biopharma has announced that its previously issued financial statements for the three and nine months ended September 30, 2023, should no longer be relied upon due to significant errors in valuation estimates. The company also warned of impending material weakness disclosures regarding internal controls and reaffirmed substantial doubt about its ability to continue as a going concern.
🚩 Red Flags
- Restatement of historical financial results (Item 4.02).
- Going concern warning: Company anticipates disclosing substantial doubt about its ability to continue as a going concern for at least 12 months.
- Material weakness in internal controls expected, adding to previously identified weaknesses from the Priveterra merger.
- Significant non-cash adjustments impacting reported losses by over $20 million.
📋 Key Facts
- Non-reliance on financial statements for the three and nine months ended September 30, 2023 (Form 10-Q filed Nov 13, 2023).
- Errors identified in valuation estimates for contingent consideration liability, convertible notes, stock-based compensation, and derivative liabilities.
- Non-cash corrections to increase reported loss by ~$22.7 million for the Predecessor Period (Jan 1 - July 21, 2023).
- Expected increase of $6.4 million in income for the Successor Period (July 22 - Sept 30, 2023).
- Contingent consideration liability expected to increase by ~$6.7 million on the balance sheet.
- Company expects to report one or more material weaknesses in internal controls over financial reporting.